Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC).

被引：1
|
作者：
Brahmer, Julie R.
Horn, Leora
Antonia, Scott J.
Spigel, David R.
Gandhi, Leena
Sequist, Lecia V.
Sankar, Vindira
Ahlers, Christoph Matthias
Wigginton, Jon M.
Kollia, Georgia
Gupta, Ashok Kumar
Gettinger, Scott N.
机构：
[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[3] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Massachusetts Gen Hosp, Boston, MA 02114 USA
[7] Bristol Myers Squibb Co, Princeton, NJ USA
[8] Yale Univ, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8030
引用
收藏
页数：1
相关论文
共 50 条
  • [41] An exploratory study of the biologic effects of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) treatment in patients (pts) with advanced (unresectable or metastatic) melanoma (MEL)
    Sosman, Jeffrey Alan
    Martin-Algarra, Salvador
    Wolchok, Jedd D.
    Sharfman, William Howard
    Bhatia, Shailender
    Hodi, F. Stephen
    Hwu, Wen-Jen
    Gajewski, Thomas
    Slingluff, Craig L.
    Kaufman, Howard
    Gupta, Manish
    McGirr, Analia
    Horak, Christine E.
    Ahlers, Christoph Matthias
    Wigginton, Jon M.
    Urba, Walter John
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).
    Grosso, Joseph
    Horak, Christine E.
    Inzunza, David
    Cardona, Diana M.
    Simon, Jason S.
    Gupta, Ashok Kumar
    Sankar, Vindira
    Park, Jong-Soon
    Kollia, Georgia
    Taube, Janis M.
    Anders, Robert
    Jure-Kunkel, Maria
    Novotny, Jim, Jr.
    Taylor, Clive R.
    Zhang, Xiaoling
    Phillips, Therese
    Simmons, Pauline
    Cogswell, John
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] A phase III comparative study of nivolumab (anti-PD-1; BMS-963558; ONO-4538) versus docetaxel in patients (pts) with previously treated advanced/metastatic nonsquamous non-small-cell lung cancer (NSCLC).
    Gettinger, Scott N.
    Brahmer, Julie R.
    Rizvi, Naiyer A.
    Ready, Neal
    Chow, Laura Quan Man
    Antonia, Scott J.
    Buyse, Marc E.
    Jassem, Jacek
    Finckenstein, Friedrich Graf
    Crino, Lucio
    Lynch, Thomas James
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] A phase 3 comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus everolimus in patients with advanced or metastatic renal cell carcinoma (mRCC) previously treated with anti-angiogenic therapy
    Motzer, R. J.
    Bono, P.
    Tomita, Y.
    Ravaud, A.
    Waxman, I.
    Gore, M. E.
    BJU INTERNATIONAL, 2013, 112 : 10 - 10
  • [45] Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer.
    Hamanishi, Junzo
    Mandai, Masaki
    Ikeda, Takafumi
    Minami, Manabu
    Kawaguchi, Atsushi
    Matsumura, Noriomi
    Abiko, Kaoru
    Baba, Tsukasa
    Yamaguchi, Ken
    Ueda, Akihiko
    Kanai, Masashi
    Mori, Yukiko
    Matsumoto, Shigemi
    Murayama, Toshinori
    Chikuma, Shunsuke
    Morita, Satoshi
    Yokode, Masayuki
    Shimizu, Akira
    Honjo, Tasuku
    Konishi, Ikuo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [46] PHASE I STUDY OF ONO-4538 (BMS-936558), AN ANTI PD-1 ANTIBODY, IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
    Yamamoto, N.
    Yamada, Y.
    Nokihara, H.
    Asahina, H.
    Shibata, T.
    Tamura, Y.
    Seki, Y.
    Honda, K.
    Tanabe, Y.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 159 - 159
  • [47] Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC.
    Rizvi, Naiyer A.
    Chow, Laura Quan Man
    Borghaei, Hossein
    Shen, Yun
    Harbison, Christopher
    Alaparthy, Suresh
    Chen, Allen C.
    Gettinger, Scott N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [48] CLINICAL ACTIVITY AND SAFETY OF ANTI-PROGRAMMED DEATH-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Gettinger, S.
    Horn, L.
    Antonia, S. J.
    Spigel, D.
    Gandhi, L.
    Sequist, L. V.
    Wigginton, J. M.
    Kollia, G.
    Gupta, A.
    Brahmer, J. R.
    ANNALS OF ONCOLOGY, 2012, 23 : 405 - 406
  • [49] A phase I dose-escalation study evaluating the effects of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with select relapsed or refractory hematologic malignancies
    Lesokhin, Alexander M.
    Gutierrez, Martin
    Halwani, Ahmad Sami
    Ansell, Stephen Maxted
    Armand, Philippe
    Borrello, Ivan
    Segota, Zdenka E.
    Cohen, Adam D.
    Talpaz, Moshe
    Cattry, Deepika
    Turner, Tracy
    Mezes, Maria
    Hartman, Christina
    Gupta, Ashok Kumar
    Kim, Su Young
    Wigginton, Jon M.
    Timmerman, John
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [50] Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM).
    Sampson, John Howard
    Viahovic, Gordana
    Desjardins, Annick
    Friedman, Henry S.
    Baehring, Joachim M.
    Hafler, David
    Rollin, Linda
    Coric, Viad
    Perez, Susan N.
    Reardon, David A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345